Cytoreductive surgery in advanced endocrine tumours of the pancreas

P. Pederzoli, M. Falconi, A. Bonora, R. Salvia, N. Sartori, C. Contro, S. Marcucci, C. Bassi

Research output: Contribution to journalArticle

Abstract

Surgery still plays an important role even in advanced endocrine tumours of the pancreas, owing to their biological behaviour. Sometimes it is possible to attempt a radical approach, but more often only cytoreduction is feasible. In fact, when the malignancy is not completely resectable on account of vessel involvement or extensive liver metastases, surgical reduction of the tumour burden (debulking) can be proposed, aimed at improving the clinical conditions and survival of these patients. Forty-one patients suffering from advanced endocrine tumour of the pancreas were observed from 1985 to 1996. In 13 patients, the disease was locally advanced as far as concerns lymph node metastases and/or vessel involvement, while the other 28 patients presented liver metastases. In the former group, we performed 6 radical resections, in the latter we submitted 2 patients to radical resection and 12 patients to cytoreductive surgery, with complete removal of the pancreatic malignancy. The overall survival of the resected patients was 87% (7/8). Three patients (37.5%) are alive and free of disease, while the other 4 have subsequently developed liver metastases. One patient died with hepatic recurrence. Half the patients (6/12) undergoing cytoreductive surgery are alive, 3 with stable and 3 with progressive disease. The other 6 patients have died due to liver progression of the disease. As data in the literature concerning the role of debulking as regards the survival are conflicting, we have modified our surgical approach in patients with advanced disease. We perform cytoreductive surgery whenever complete removal of the pancreatic tumour is feasible. The rationale of this approach is to leave only a liver with residual disease, with a view to giving targeted adjuvant treatment.

Original languageEnglish
JournalItalian Journal of Gastroenterology and Hepatology
Volume31
Issue numberSUPPL. 2
Publication statusPublished - 1999

Fingerprint

Islets of Langerhans
Neoplasms
Liver
Neoplasm Metastasis
Survival
Tumor Burden
Liver Diseases
Lymph Nodes
Recurrence

Keywords

  • Cytoreductive surgery
  • Metastatic endocrine tumours
  • Pancreatic endocrine tumours

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Pederzoli, P., Falconi, M., Bonora, A., Salvia, R., Sartori, N., Contro, C., ... Bassi, C. (1999). Cytoreductive surgery in advanced endocrine tumours of the pancreas. Italian Journal of Gastroenterology and Hepatology, 31(SUPPL. 2).

Cytoreductive surgery in advanced endocrine tumours of the pancreas. / Pederzoli, P.; Falconi, M.; Bonora, A.; Salvia, R.; Sartori, N.; Contro, C.; Marcucci, S.; Bassi, C.

In: Italian Journal of Gastroenterology and Hepatology, Vol. 31, No. SUPPL. 2, 1999.

Research output: Contribution to journalArticle

Pederzoli, P, Falconi, M, Bonora, A, Salvia, R, Sartori, N, Contro, C, Marcucci, S & Bassi, C 1999, 'Cytoreductive surgery in advanced endocrine tumours of the pancreas', Italian Journal of Gastroenterology and Hepatology, vol. 31, no. SUPPL. 2.
Pederzoli, P. ; Falconi, M. ; Bonora, A. ; Salvia, R. ; Sartori, N. ; Contro, C. ; Marcucci, S. ; Bassi, C. / Cytoreductive surgery in advanced endocrine tumours of the pancreas. In: Italian Journal of Gastroenterology and Hepatology. 1999 ; Vol. 31, No. SUPPL. 2.
@article{9b7cddf4bd9f422c86a181e2a4bae863,
title = "Cytoreductive surgery in advanced endocrine tumours of the pancreas",
abstract = "Surgery still plays an important role even in advanced endocrine tumours of the pancreas, owing to their biological behaviour. Sometimes it is possible to attempt a radical approach, but more often only cytoreduction is feasible. In fact, when the malignancy is not completely resectable on account of vessel involvement or extensive liver metastases, surgical reduction of the tumour burden (debulking) can be proposed, aimed at improving the clinical conditions and survival of these patients. Forty-one patients suffering from advanced endocrine tumour of the pancreas were observed from 1985 to 1996. In 13 patients, the disease was locally advanced as far as concerns lymph node metastases and/or vessel involvement, while the other 28 patients presented liver metastases. In the former group, we performed 6 radical resections, in the latter we submitted 2 patients to radical resection and 12 patients to cytoreductive surgery, with complete removal of the pancreatic malignancy. The overall survival of the resected patients was 87{\%} (7/8). Three patients (37.5{\%}) are alive and free of disease, while the other 4 have subsequently developed liver metastases. One patient died with hepatic recurrence. Half the patients (6/12) undergoing cytoreductive surgery are alive, 3 with stable and 3 with progressive disease. The other 6 patients have died due to liver progression of the disease. As data in the literature concerning the role of debulking as regards the survival are conflicting, we have modified our surgical approach in patients with advanced disease. We perform cytoreductive surgery whenever complete removal of the pancreatic tumour is feasible. The rationale of this approach is to leave only a liver with residual disease, with a view to giving targeted adjuvant treatment.",
keywords = "Cytoreductive surgery, Metastatic endocrine tumours, Pancreatic endocrine tumours",
author = "P. Pederzoli and M. Falconi and A. Bonora and R. Salvia and N. Sartori and C. Contro and S. Marcucci and C. Bassi",
year = "1999",
language = "English",
volume = "31",
journal = "Digestive and Liver Disease",
issn = "1590-8658",
publisher = "Elsevier B.V.",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Cytoreductive surgery in advanced endocrine tumours of the pancreas

AU - Pederzoli, P.

AU - Falconi, M.

AU - Bonora, A.

AU - Salvia, R.

AU - Sartori, N.

AU - Contro, C.

AU - Marcucci, S.

AU - Bassi, C.

PY - 1999

Y1 - 1999

N2 - Surgery still plays an important role even in advanced endocrine tumours of the pancreas, owing to their biological behaviour. Sometimes it is possible to attempt a radical approach, but more often only cytoreduction is feasible. In fact, when the malignancy is not completely resectable on account of vessel involvement or extensive liver metastases, surgical reduction of the tumour burden (debulking) can be proposed, aimed at improving the clinical conditions and survival of these patients. Forty-one patients suffering from advanced endocrine tumour of the pancreas were observed from 1985 to 1996. In 13 patients, the disease was locally advanced as far as concerns lymph node metastases and/or vessel involvement, while the other 28 patients presented liver metastases. In the former group, we performed 6 radical resections, in the latter we submitted 2 patients to radical resection and 12 patients to cytoreductive surgery, with complete removal of the pancreatic malignancy. The overall survival of the resected patients was 87% (7/8). Three patients (37.5%) are alive and free of disease, while the other 4 have subsequently developed liver metastases. One patient died with hepatic recurrence. Half the patients (6/12) undergoing cytoreductive surgery are alive, 3 with stable and 3 with progressive disease. The other 6 patients have died due to liver progression of the disease. As data in the literature concerning the role of debulking as regards the survival are conflicting, we have modified our surgical approach in patients with advanced disease. We perform cytoreductive surgery whenever complete removal of the pancreatic tumour is feasible. The rationale of this approach is to leave only a liver with residual disease, with a view to giving targeted adjuvant treatment.

AB - Surgery still plays an important role even in advanced endocrine tumours of the pancreas, owing to their biological behaviour. Sometimes it is possible to attempt a radical approach, but more often only cytoreduction is feasible. In fact, when the malignancy is not completely resectable on account of vessel involvement or extensive liver metastases, surgical reduction of the tumour burden (debulking) can be proposed, aimed at improving the clinical conditions and survival of these patients. Forty-one patients suffering from advanced endocrine tumour of the pancreas were observed from 1985 to 1996. In 13 patients, the disease was locally advanced as far as concerns lymph node metastases and/or vessel involvement, while the other 28 patients presented liver metastases. In the former group, we performed 6 radical resections, in the latter we submitted 2 patients to radical resection and 12 patients to cytoreductive surgery, with complete removal of the pancreatic malignancy. The overall survival of the resected patients was 87% (7/8). Three patients (37.5%) are alive and free of disease, while the other 4 have subsequently developed liver metastases. One patient died with hepatic recurrence. Half the patients (6/12) undergoing cytoreductive surgery are alive, 3 with stable and 3 with progressive disease. The other 6 patients have died due to liver progression of the disease. As data in the literature concerning the role of debulking as regards the survival are conflicting, we have modified our surgical approach in patients with advanced disease. We perform cytoreductive surgery whenever complete removal of the pancreatic tumour is feasible. The rationale of this approach is to leave only a liver with residual disease, with a view to giving targeted adjuvant treatment.

KW - Cytoreductive surgery

KW - Metastatic endocrine tumours

KW - Pancreatic endocrine tumours

UR - http://www.scopus.com/inward/record.url?scp=0032744207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032744207&partnerID=8YFLogxK

M3 - Article

C2 - 10604132

AN - SCOPUS:0032744207

VL - 31

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

IS - SUPPL. 2

ER -